Free Fatty Acid Effects In Type 2 Diabetes
- Status
- Enrolling by invitationResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids
- Interventions
- Omega-3 Fatty Acids; Semaglutide 0.25 mg; Placebo
- Conditions
- Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids
- Phase and size
- NA · 60 participants
- Dates
- Start 2026-09
Primary completion 2026-12 - Sponsor
- University of Ulster (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo.From baseline to 28 days of treatment
02Eligibility
Who can take part
Inclusion Criteria: * Individuals who are over 18 years of age with a BMI between 25-50 kg/m2, and who have been diagnosed with T2DM (\>7.0 mmol/l fasting glucose) or pre-diabetes (impaired glucose tolerant 5.0-6.9mmol/l) and are either on no medication, are diet controlled or taking metformin. Participants may also have a history of cardiovascular disease. Exclusion Criteria: * Those who have severe or unstable cardiovascular disease * Type 2 diabetics or prediabetics who are on an anti-diabetic medication (with the exception of metformin) * Undergone recent major surgery or planned surgery during the study period * Have implanted devices (such as pacemakers or defibrillators) * Have an active infection * Are involved in any other type of weight loss study/intervention * Are pregnant/breastfeeding.
03Change log
Registry changes
No changes recorded since the trial was added.